Azienda USL Toscana Centro, Gynecology and Obstetric Department, Santo Stefano Hospital, 59100 Prato, Italy.
Azienda USL Toscana Centro, Gynecology and Obstetric Department, Santa Maria Annunziata Hospital, 50012 Florence, Italy.
Int J Mol Sci. 2021 Nov 12;22(22):12248. doi: 10.3390/ijms222212248.
Endometrial cancer is the most frequent gynecological malignancy, and, although epidemiologically it mainly affects advanced age women, it can also affect young patients who want children and who have not yet completed their procreative project. Fertility sparing treatments are the subject of many studies and research in continuous evolution, and represent a light of hope for young cancer patients who find themselves having to face an oncological path before fulfilling their desire for motherhood. The advances in molecular biology and the more precise clinical and prognostic classification of endometrial cancer based on the 2013 The Cancer Genome Atlas classification allow for the selection of patients who can be submitted to fertility sparing treatments with increasing oncological safety. It would also be possible to predict the response to hormonal treatment by investigating the state of the genes of the mismatch repair.
子宫内膜癌是最常见的妇科恶性肿瘤，尽管从流行病学角度来看，它主要影响老年妇女，但也可能影响那些想要孩子、尚未完成生育计划的年轻患者。保留生育能力的治疗方法是许多研究和不断发展的研究的主题，对于那些在实现母性愿望之前不得不面对肿瘤治疗的年轻癌症患者来说，这是一线希望。分子生物学的进步，以及基于 2013 年癌症基因组图谱分类的更精确的临床和预后子宫内膜癌分类，使得选择能够以更高的肿瘤安全性接受保留生育能力治疗的患者成为可能。通过研究错配修复基因的状态，也有可能预测激素治疗的反应。
